AstraZeneca plc vs VanEck Gold Miners ETF — how do they compare? AstraZeneca plc trades at $158.6 (market cap $248.14B), while VanEck Gold Miners ETF trades at $91.22. The key difference: AstraZeneca plc pays a 2.01% dividend while VanEck Gold Miners ETF pays none, and VanEck Gold Miners ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | GDX | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | — |
52-Week High | $209.48 | $115.84 |
52-Week Low | $147.06 | $56.60 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
GDX trades at $90.92, up 0.48% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional repositioning and strong gold price momentum driving miner performance. The ETF offers diversified exposure to gold mining equities, though key valuation ratios are not publicly detailed for the fund itself.
The outlook is supported by gold's rally and potential for miner catch-up, but risks include gold price volatility and sector underperformance relative to bullion. Analyst sentiment is mixed, with some seeing value in miners after recent gains, while technical indicators warn of near-term overextension.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →